Charlotte Robinson

DocwireNews

There are existing prediction tools to help determine the risk of disease progression in IgA nephropathy (IgAN). Whereas the adult International IgAN Prediction Tool can be used 1 or 2 years post-biopsy, the pediatric tool can only be used at biopsy. This limits the ability to reevaluate pediatric patient risk after a period of treatment. To address this disparity, Sean J. Barbour, MD, and other researchers attempted to develop an updated pediatric prediction tool for post-biopsy use. Their report appeared in Kidney International.The original pediatric prediction tool comprises two models with or without ethnicity plus other predictor variables that can be used in children at the time of biopsy. The purpose of this analysis was to move the &ldquo;baseline&rdquo; time point to a new landmark 1 year after biopsy. However, due to a limited number of outcome events, it was not possible to refit a new model at this new baseline time point. Instead, Barbour et al updated the adult post-biopsy prediction tool models, intended for use in adults 1 year post-biopsy, for use in children.The researchers utilized an international, multiethnic cohort of 947 children with biopsy-proven IgAN and frequent follow-up into adulthood to update the adult post-biopsy prediction tool models. The patients they studied were &lt;18 years of age 1 year after kidney biopsy. Those who progressed to end-stage renal disease (ESRD) within the first year, had less than 1 year of follow-up, or did not have at least one estimated glomerular filtration rate (eGFR) measurement before and after the new landmark time of 1 year after biopsy were excluded to ensure adequate baseline and longitudinal follow-up eGFR data.The primary outcome was a composite of the first incidence of ESRD (eGFR &lt;15 mL/min/1.73 m2, dialysis, or transplantation) or a permanent reduction in eGFR below 30% of the value at the 1-year landmark time. The purpose of the analysis was to predict the risk of the primary outcome in children using models applied at a baseline time point 1 year after biopsy.The researchers found that neither the adult post-biopsy tool nor the original pediatric prediction tool models have adequate prediction performance to be used without modification in children 1 year after biopsy. The original pediatric prediction tool should be used at the time of biopsy, and the updated pediatric prediction tool should be used to reevaluate risk at 1 or 2 years after biopsy.Compared with the original pediatric prediction tool, the updated post-biopsy prediction tool had a better model fit, with higher R2D (51%/50% vs 20%), significant increase in 4-year C-statistics (0.83 vs 0.73/0.69), and better 4-year calibration with lower integrated calibration indices (0.74/0.54 vs 2.45/1.01). The results were similar after internal validation and when the models were applied 2 years post-biopsy.At 1 and 2 years after biopsy, children with higher predicted risk started with a lower eGFR and experienced a more rapid decline over time. Among all risk groups, eGFR had a variable rate of increase until 15-18 years of age; then it decreased linearly, with a more rapid decline in higher-risk groups.&ldquo;In conclusion,&rdquo; the authors summarized, &ldquo;we used a large, international, multiethnic cohort to generate the pediatric post-biopsy prediction tool that can be used in children with IgAN 1 or 2 years after biopsy to predict the risk of disease progression. This tool allows for reevaluation of individual patient risk after supportive care or immunosuppression treatment implemented in the first 2 years after biopsy.&rdquo;Source: <a href="https://doi.org/10.1016/j.kint.2024.07.012" target="_blank" rel="noopener">Kidney International</a>&nbsp;

Jordana Jampel

Cutaneous Melanoma: Sun Protection Behaviors and UV Exposure in Canada

Melanoma

Leah Lawrence

Significant Cardiac Benefit Seen With Ifetroban in Patients With Duchenne Muscular Dystrophy

Neurology

Apitegromab Improved Motor Function in Type 2/3 Spinal Muscular Atrophy

Latest News

Updated Pediatric IgAN Prediction Tool for Post-Biopsy Use

IgA Nephropathy

Researchers developed an updated pediatric prediction tool to determine risk for IgA nephropathy (IgAN) post-biopsy. The current tool can only be used at biopsy.

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe